Why · The Premise
The infrastructure between biologics candidate and patient is being rebuilt. Biology moves faster than the systems designed to carry it. The leaders who own the plant, sign the batch and carry the accountability for what the intelligence layer recommends — they meet here.
01
Every biologics leader is asked the same question. How does discovery become medicine at scale. With the platform that holds. The infrastructure between candidate and patient is being rebuilt.
02
The white space is the room that holds the conversation differently. Closed-door. By invitation. End-user led. No expo hall. No vendor pitch. A circle for the leaders building what comes next.
03
the Conversation. BILS is that room. Senior biologics leadership convened around the work that compounds. Upstream. Downstream. CDMO. Digital manufacturing and supply. Less noise. More signal.
04
In the Conversation. Senior faculty drawn from the leaders who own the plant, sign the batch and carry the accountability. Announced in cadence with the programme.
Thesis · The Room
The gap.
Biology moves faster than the infrastructure designed to carry it. Process validation still needs a human signature. The recommendation behind it is now algorithmic. The compliance gap between model output and accountability has never been formally named.
The Conversation.
BILS convenes the leaders building the infrastructure that closes that gap · across upstream bioprocessing · downstream purification · CDMO strategy · digital manufacturing and supply. The corridor where biologics ambition becomes clinical supply · or breaks.
The decision.
What scales. What purifies. Who manufactures the future. Three questions the room must hold before the process locks. For the leaders who own the plant, sign the batch and are accountable for the intelligence layer no one has formally governed.
"Not an event. It is a tradition."
Uwe Gottschalk · Former CSO Lonza · Operating Partner, Keensight Capital · Conference Chair
In the Conversation
Conference Chair
Uwe Gottschalk
Operating Partner · Keensight Capital
Former CSO · Lonza
Jens Vogel
Vice President · MSD
Nuno Fontes
WuXi Biologics
Dénes Zalai
Eleva Biologics
Felix Oehme
Former Bayer
Jose Martinez
Almirall
Judy Chou
AltruBio
Who Attends
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
Who attends.
30 partner SVGs from ./logos/ · read from disk · never reconstruct
150
senior leaders · up to
80/20
end-user · partner
2 days
Berlin · closed-door
70%+
VP and above
the circle. · access
The prospectus is not public. Shared directly with the organisations that belong in the room.
No access code? Contact Herbert →
For the few. Shaping the future.
What scales.
What purifies.
Who manufactures the future.